-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

Benzinga·10/02/2026 13:08:50
Listen to the news
Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.